Drug-drug:
- Concurrent use of strong or moderate CYP3A4 inhibitors, including atazanavir, ciprofloxacin, clarithromycin, conivaptan, diltiazem, erythromycin, fluconazole, fosamprenavir, itraconazole, ketoconazole, nelfinavir, posaconazole, ritonavir, and verapamil, significantly ↑ levels and the risk of toxicity; concurrent use contraindicated. Wait 2 wk after discontinuing inhibitor before initiating flibanserin. If initiating inhibitor, wait two days after last dose of flibanserin.
- Concurrent use with alcohol↑ risk of hypotension/syncope and excess sedation; wait ≥2 hr after consuming 12 standard alcoholic drinks before taking dose at bedtime; skip bedtime dose if consumed ≥3 standard alcoholic drinks.
- Concurrent use of oral hormonal contraceptives and weak CYP3A4 inhibitors including cimetidine, and fluoxetine may ↑ levels and the risk of toxicity; avoid concurrent use with multiple weak CYP3A4 inhibitors.
- Strong CYP2C19 inhibitors, including proton pump inhibitors, SSRIs, benzodiazepines, and antifungals, ↑ levels and the risk of toxicity; concurrent use should be undertaken with caution.
- CYP3A4 inducers, including carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and rifapentine, ↓ levels and effectiveness; concurrent use not recommended.
- ↑digoxin and sirolimus levels and the risk of toxicity; careful monitoring recommended
- ↑risk of CNS depression with other CNS depressants, including alcohol, antihistamines, opioids, sedative/hypnotics, some anti-anxiety agents, antidepressants, and antipsychotics.
Natural-Natural Products:
- Concurrent use with gingko may ↑ levels and the risk of toxicity; avoid use with other weak CYP3A4 inhibitors.
- St. John's wort↓ levels and effectiveness; concurrent use not recommended.
Drug-Food:
- Grapefruit juice↑ levels and the risk of toxicity; concurrent ingestion contraindicated.
Therapeutic Classification: sexual dysfunction agents
Absorption: Moderately absorbed (33%) following oral administration.
Distribution: Unknown.
Protein Binding: 98%.
Metabolism/Excretion: Primarily metabolized in the liver, via the CYP3A4 isoenzyme, and to a lesser extent by the CYP2C19 isoenzyme; the CYP2C19 isoenzyme exhibits genetic polymorphism; poor metabolizers may have significantly ↑ flibanserin concentrations and an ↑ risk of adverse effects. 44% excreted in urine, 51% in feces almost entirely as metabolites, which do not appear to be pharmacologically active.
Half-Life: 11 hr.